GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Land And Improvements

OKUR (OnKure Therapeutics) Land And Improvements : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics Land And Improvements?

OnKure Therapeutics's land and improvements for the quarter that ended in Dec. 2024 was $0.00 Mil.


OnKure Therapeutics Land And Improvements Historical Data

The historical data trend for OnKure Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics Land And Improvements Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Land And Improvements
- - -

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Land And Improvements Get a 7-Day Free Trial Premium Member Only - - - - -

OnKure Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


OnKure Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.